Home LiteratureArticle Details
PMID: 9455808 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.

International journal of cancer ·Vol. 75 ·No. 3 ·1998-01-30 ·Pages 451-8

Schneider J, Brichard V, Boon T, Meyer zum Büschenfelde KH, Wölfel T

Abstract

From the peripheral blood lymphocytes (PBLs) of melanoma patient SK29(AV) we have previously isolated 2 independent cytolytic T lymphocyte (CTL) clones (CTL7/147 and CTL13/211), which lysed autologous tumor cells in association with HLA-B45.1. As demonstrated here, both CTL clones were directed against melanocyte differentiation antigen Melan-A/MART-1, which also was recognized by HLA-A2.1-restricted CTLs from the same patient. By generating and transfecting 3'-deletion mutants of Melan-A/MART-1 cDNA, we localized its peptide-coding regions. The HLA-B45.1-presented peptides were derived from a hydrophobic region of the protein and largely overlapped the peptides recognized by CTLs from the same patient in association with HLA-A2.1. We determined the fine specificity of these CTL clones with synthetic peptides. CTL clone CTL7/147 recognized the 11-mer peptide AEEAAGIGILT (residues 24-34) at the lowest concentrations. The absence of threonine-34 abrogated the recognition by CTL7/147. The truncated peptide AEEAAGIGIL (residues 24-33) proved to be the optimal synthetic peptide for sensitization against lysis by CTL13/211. This indicated that C-terminal threonine-34 was not involved in binding to HLA-B45.1 but, rather, was part of the epitope for CTL7/147. HLA-B45.1-associated peptides of Melan-A/MART-1 were regularly processed and presented by other melanomas and other cell types. Three of 4 independent HLA-A2.1-restricted SK29-CTL clones recognized the 10-mer peptide EAAGIGILTV (residues 26-35) at 10- to 100-fold lower concentrations than the nonamer AAGIGILTV (residues 27-35), previously described as the common immunodominant peptide antigen for all known anti-Melan-A/MART-1 CTLs restricted by HLA-A2.1. Different melanoma peptide antigens currently are applied in therapeutic vaccination studies. Our findings emphasize that restricting to peptides of minimal length might exclude relevant T-cell epitopes.

MeSH Terms
Amino Acid Sequence Animals Antigens, Neoplasm/genetics,immunology Base Sequence COS Cells DNA, Neoplasm/genetics Epitopes, T-Lymphocyte/immunology HLA-A2 Antigen/immunology HLA-B Antigens/immunology Humans MART-1 Antigen Melanoma/genetics,immunology,metabolism Neoplasm Proteins/genetics,immunology Sequence Homology, Amino Acid T-Lymphocytes, Cytotoxic/immunology Tumor Cells, Cultured
Chemicals
Antigens, Neoplasm DNA, Neoplasm Epitopes, T-Lymphocyte HLA-A2 Antigen HLA-B Antigens HLA-B45 antigen MART-1 Antigen MLANA protein, human Neoplasm Proteins
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Schneider J
I Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz, Germany.
Brichard V
Boon T
Meyer zum Büschenfelde K H
Wölfel T
Article Info
Journal
International journal of cancer
Abbr.
Int J Cancer
ISSN
0020-7136
Published
1998-01-30
Pages
451-8
Language
English
Region
United States
NLM ID
0042124
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com